Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082220 | 0.87 | NPC1 (0.61) | GRM4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL14082429 | 0.83 | RXFP1 (0.60) | KDM4ENPSR1RXFP1GRM4KMT2A | |
| SCHEMBL14083481 | 0.82 | RXFP1 (0.66) | KDM4ENPSR1RXFP1GRM4KMT2A | |
| SCHEMBL8804658 | 0.82 | KDM4E (0.82) | KDM4ENPSR1RXFP1GRM4KMT2A | |
| SCHEMBL14082273 | 0.82 | RAB9A (0.72) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL14313610 | 0.82 | TRPV1 (0.72) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL24298091 | 0.81 | GRM4 (0.67) | KDM4ENPSR1RXFP1GRM4KMT2A | |
| SCHEMBL29496337 | 0.81 | GRM4 (0.67) | KDM4ENPSR1RXFP1GRM4KMT2A | |
| SCHEMBL14082248 | 0.81 | RAB9A (0.69) | KMT2AMEN1NPC1RAB9ATRPV1 | |
| SCHEMBL14082212 | 0.81 | NPC1 (0.68) | GRM4NPC1RAB9ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | KDM4E 4231/4885NPSR1 406/4885RXFP1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.